A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Cancer metastases; Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms ADAM
- 14 Mar 2024 Planned End Date changed from 1 Jul 2025 to 18 Feb 2029.
- 14 Mar 2024 Planned primary completion date changed from 1 Jul 2025 to 30 Apr 2026.
- 14 Mar 2024 Status changed from recruiting to active, no longer recruiting.